ACIU
AC Immune LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$274.79M
P/E Ratio
—
EPS
$-0.88
Beta
1.63
52W High
$4.00
52W Low
$1.43
50-Day MA
$2.97
200-Day MA
$2.80
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
11.24
PEG Ratio
0.00
About AC Immune Ltd
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Fundamentals
| Revenue (TTM) | $3.57M |
| Gross Profit (TTM) | $-52.86M |
| EBITDA | $-67.47M |
| Operating Margin | -4262.00% |
| Return on Equity | -89.60% |
| Return on Assets | -22.40% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $0.55 |
| Price-to-Book | 4.99 |
| Price-to-Sales (TTM) | 76.91 |
| EV/Revenue | 38.41 |
| EV/EBITDA | -0.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -70.30% |
| Shares Outstanding | $101.77M |
| Float | $38.39M |
| % Insiders | 31.19% |
| % Institutions | 25.52% |
Analyst Ratings
Consensus ($8.92 target)
4
BuyData last updated: 4/7/2026